Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announced impressive results from a peer-reviewed retrospective study which examined the integration of wide field optical coherence tomography (WF-OCT) with the company’s proprietary investigation ImgAssist AI technology.
The company said that the study showed its AI algorithm when integrated in the WF-OCT accurately identified 96.8% of pathology-positive breast cancer margins.
Perimeter said these results demonstrated the clinical viability of AI-enhanced margin visualization using WF-OCT in breast cancer surgery and its potential to decrease reoperation rates due to residual tumors.
“We have a training dataset of several million proprietary images of both cancerous and healthy tissue captured with our OCT imaging technology,” Perimeter CEO Adrian Mendes said in a statement.
“Our world-class AI team has developed models tailored for real-time applications in healthcare settings and used our vast image library to train these models to achieve an industry-leading result.”
Perimeter’s B-Series OCT in combination with its ImgAssist AI software is currently being evaluated for breast conservation surgery in an ongoing clinical trial led by Dr. Alistair Thompson at Baylor College of Medicine.
An interim analysis of data from this trial is expected to be carried out in the second quarter of 2024. The trial is set to wrap up by the year-end.